艾迪注射液对荷H_(22)瘤小鼠免疫作用的影响

Effect of Aidi(AD) Injection on the Immune Function of the Mouse Bearing H_(22) Tumor

目的研究艾迪注射液的抗癌活性,探讨其增强免疫力的作用与机制。方法①取Balb/c小鼠50只,随机平均分为5组,每组10只,模型组和3个给药组小鼠均腋下接种H22瘤细胞悬液(2×107个.mL-1)0.2 mL。24 h后对3个给药组小鼠按低、中、高3个浓度分别腹腔注射艾迪注射液1,2,3 g.kg-1(药物浓度分别为100,200,300mg.mL-1);模型组小鼠腹腔注射给予0.9%氯化钠注射液0.2 mL。均为qd,连续5 d。正常组小鼠不给予任何处理。第5天所有小鼠均腹腔注射20%绵羊红细胞(SRBC)悬液0.2 mL并持续给药。第10天经小鼠眼眶取血,采用溶血素抗体测定法测定半数溶血时的吸光度值(HC50)。②取Balb/c小鼠50只,分组及H22瘤细胞悬液接种方法同上。3个给药组小鼠按低、中、高剂量(分别为1,2,3 g.kg-1,给药浓度分别为100,200,300 mg.mL-1,均为qd)连续11 d腹腔注射给予艾迪注射液,模型组腹腔注射给予0.9%氯化钠注射液0.2 mL,均为qd。正常组不给予任何处理。第12天称各组小鼠体重,计算脾脏、胸腺指数。采用酶联免疫吸附法检测艾迪注射液对各组小鼠IgG、IL-2、TNF-α的影响。结果与模型组小鼠比较,正常组和给予艾迪注射液的各组小鼠的HC50值均明显增高(均P<0.01),脾和胸腺指数(除高浓度组胸腺指数外)亦均明显增高(均P<0.01)。艾迪注射液还可有效增加荷瘤Balb/c小鼠IgG、IL-2、TNF-a的生成。结论艾迪注射液可明显提高荷瘤小鼠免疫力。

Objective To study the anticancer activity of Aidi （AD） injection and probe into its immunoenhancing effect as well as the corresponding mechanisms. Methods Experiment①： 50 Balb/c mice were randomly divided into 5 equal groups： control group, model group and three trial groups. Mice of the model group and trial groups were given each a hypodermic injection of 0.1 mL of Ha tumor cell suspension （ containing 2×10^7 cells·mL^-1） at the subaxillary region. Mice of the control group were given no injection. 24 hours later, mice of the three trial groups were given each an intraperitoneal injection of AD injection at lose dose （ 1 g·kg^-1 in 0.2 mL）, medium dose （2 g·kg^-1 in 0.2 mL） and high dose （3 g·kg^-1 in 0.2 mL）, respectively. The injections were given once daily for 5 consecutive days. Mice of the control group and model group were given intraperitoneal injections oFequivalent amounts of 0.9% sodium chloride solution q. d. for 5 days as well. On the 5^th day of the experiment, mice of all the 5 groups were given each an intraperitoneal injection of 0.2 mL of 20% SRBC （sheep red blood cells） suspension and the afore mentioned treatment for different groups of mice was continued for another 5 days. On the 10^th day, blood samples were taken from the postorbital venous plexuses of the animals. The value of abserbance at the 50% hemolytic dose （HC50） was assayed with the antihemolysin antibody method. Experiment②： 50 Balb/c mice were divided and inoculated with suspensions of H22 tumor ceils in the same manner as described in Experiment ①. 24 h later, mice of the 3 trial groups were given intraperitoneal injections of AD injection at the same low dose, medium dose and high dose, respectively, as described in Experiment ②. These injections, however, lasted 11 days. Mice of the control group and model group were given intraperitoneal injections of equivalent amounts of 0.9% sodium chloride solution for 11 days as well. On the 12^th day of the experiment, the body weight of each mouse was noted down and the animals were sacrificed after blood samples had been taken. The spleen index and thymus index were calculated and serum concentrations of IgG, IL-2, TNF-α determined with ELISA. Results The HC50 value of the mice of the control group and three trial groups treated with AD injection were significantly higher than those of the mice of the model group（P 〈0.01 ）. The spleen index and thymus index of the mice of the control group and three trial groups were also strikingly greater than those of the mice of the model group （P 〈 0.05 or P 〈 0.01 ）. Besides AD injection was shown to dramatically increase the production of IgG, IL-2 and TNF-α in tumor-bearing Balb/c mice. Condusion AD injection was shown to strikingly enhance the immune function of tumor-bearing mice.